Author: Laura Riva; Shuofeng Yuan; Xin Yin; Laura Martin-Sancho; Naoko Matsunaga; Sebastian Burgstaller-Muehlbacher; Lars Pache; Paul P. De Jesus; Mitchell V. Hull; Max Chang; Jasper Fuk-Woo Chan; Jianli Cao; Vincent Kwok-Man Poon; Kristina Herbert; Tu-Trinh Nguyen; Yuan Pu; Courtney Nguyen; Andrey Rubanov; Luis Martinez-Sobrido; Wen-Chun Liu; Lisa Miorin; Kris M. White; Jeffrey R. Johnson; Christopher Benner; Ren Sun; Peter G. Schultz; Andrew Su; Adolfo Garcia-Sastre; Arnab K. Chatterjee; Kwok-Yung Yuen; Sumit K. Chanda
Title: A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals Document date: 2020_4_17
ID: 1fgnfh62_26
Snippet: Replication. One of the most efficient ways to identify antiviral candidates against an emergent virus, such as SARS-CoV-2, that can be rapidly evaluated in clinical trials is to repurpose clinically assessed drugs. Given the urgent need for therapeutics to treat SARS-CoV-2 infection, we developed a high-throughput assay to screen a comprehensive repurposing library. Vero E6 cells, kidney epithelial cells derived from an African green monkey, hav.....
Document: Replication. One of the most efficient ways to identify antiviral candidates against an emergent virus, such as SARS-CoV-2, that can be rapidly evaluated in clinical trials is to repurpose clinically assessed drugs. Given the urgent need for therapeutics to treat SARS-CoV-2 infection, we developed a high-throughput assay to screen a comprehensive repurposing library. Vero E6 cells, kidney epithelial cells derived from an African green monkey, have been shown to be highly permissive to SARS-CoV-2 infection 42 and viral replication can be assessed through measurement of viral-induced cytopathic effects (CPE) 43 . A clinical isolate of the SARS-CoV-2 virus (SARS-CoV-2 author/funder. All rights reserved. No reuse allowed without permission.
Search related documents:
Co phrase search for related documents- african green monkey and clinical trial: 1
- african green monkey and CPE cytopathic effect: 1, 2, 3, 4, 5, 6, 7, 8
- african green monkey and cytopathic effect: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- african green monkey and epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9
- african green monkey and green monkey: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- african green monkey and high throughput: 1, 2
- african green monkey and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- african green monkey and SARS infection treat: 1
- african green monkey and SARS virus: 1, 2, 3, 4, 5, 6, 7
- african green monkey and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral candidate and clinical trial: 1, 2, 3, 4, 5, 6
- antiviral candidate and cytopathic effect: 1, 2, 3, 4
- antiviral candidate and high throughput: 1, 2, 3, 4, 5, 6
- antiviral candidate and high throughput assay: 1, 2, 3, 4, 5
- antiviral candidate and high throughput assay develop: 1
- antiviral candidate and SARS infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- antiviral candidate and SARS virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral candidate and urgent need: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- antiviral candidate and viral replication: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27
Co phrase search for related documents, hyperlinks ordered by date